[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559190":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":48,"collaborators":20,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":20,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":20,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Royal Marsden NHS Foundation Trust","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PSMA PET-CT","EXPERIMENTAL","Within the two weeks prior to surgery, the patients will undergo both PSMA PET-CT \\& FDG PET-CT scans at least 48 hours apart.\n\nThe Investigational Medicinal Product (IMP) under investigation in this trial is 68Ga-PSMA. This is an imaging radionuclide tracer.",[13],"Drug: 68Ga-PSMA",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","68Ga-PSMA","This is an imaging radionuclide tracer and is in chemical form. Up to 200 MBq. Route of administration is Intravenous.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Myles Smith","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Reyhaneh Sadegh Zadeh","CONTACT","020 7352 8171","reyhaneh.sadeghzadeh@rmh.nhs.uk",[32],{"facility":33,"status":34,"city":35,"state":20,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"The Royal Marsden NHS Foundation Trust","RECRUITING","London","SW3 6JJ","United Kingdom","UK",{"type":40,"coordinates":41},"Point",[42,43],-0.12574,51.50853,{"lat":43,"lon":42},[46,47],{"name":27,"role":28,"phone":20,"phoneExt":20,"email":30},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100559190","phase-2-preoperative-planning-with-psma-pet-in-melanoma-surgery-trial-100559190",false,"NCT06560905","Preoperative Planning With PSMA-PET in Melanoma Surgery Trial","PPPIMS","Inclusion Criteria:\n\n* Males ≥18 years of age\n* Biopsy proven first and recurrent metastatic melanoma with palpable nodal disease who have undergone a staging FDG PET-CT scan as part of routine clinical care and are scheduled for surgery for resection of the primary site\n\nExclusion Criteria:\n\n* Patients unable to give voluntary written informed consent to participate in this study\n* Patients not willing to complete all the study assessments\n* Patients who are females\n* Patients who are taking androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists.\n* Patients who have or have previously been diagnosed with prostate cancer\n* Patients who have had Lu-177 PSMA therapy or barium studies within a period of 10 days prior to undergoing PSMA PET-CT scanning\n* Patients not fluent in English","MALE","18 Years",{"count":60,"type":61},16,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET\u002F CT.",[67],"Malignant Melanoma","2025-06-26",{"date":70,"type":71},"2025-07-01","ACTUAL",{"date":73,"type":71},"2025-03-11",{"date":75,"type":61},"2025-12-31",{"name":5,"class":6},1]